Voprosy virusologii · 2026
[Influenza virus infection affects the efficacy of the treatment of dyslipidemia in mice with a polyisoprenoid-based drug].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Makiev E A, Kozhevnikova T N, Pronin A V, Narovlyansky A N, Sanin A V, Ganshina I V, Shmarov M M
Аннотация
OBJECTIVE: To evaluate how influenza infection affects the hypolipidemic effect of a novel combined drug - Prenophytol based on polyisoprenoids (sodium polyprenyl phosphate and beta-sitosterol) in mice with experimental dyslipidemia.
MATERIALS AND METHODS: In BALB/c mice with experimentally induced dyslipidemia, the impact of Prenophytol on lipid metabolism parameters was assessed. Currently the drug is at the stage of clinical trials (Roszdravnadzor's permission to conduct clinical trials No. 362 dated 08/14/2025). A subset of animals was infected with influenza A/California/07/2009 (H1N1) virus.
RESULTS: Administration of the drug to dyslipidemia mice resulted in a significant reduction in total cholesterol, triglycerides, and LDL levels, along with a significant increase in HDL. However, in the presence of influenza infection, the hypolipidemic effect of Prenophytol was markedly attenuated: only cholesterol levels decreased significantly, whereas changes in triglycerides, LDL, and HDL did not reach statistical significance.
CONCLUSIONS: Influenza infection diminishes the therapeutic efficacy of the Prenophytol in the treatment of dyslipidemia. These findings indicate that concomitant viral infections must be taken into account when designing dyslipidemia treatment regimens and conducting clinical trials of this drug.
MATERIALS AND METHODS: In BALB/c mice with experimentally induced dyslipidemia, the impact of Prenophytol on lipid metabolism parameters was assessed. Currently the drug is at the stage of clinical trials (Roszdravnadzor's permission to conduct clinical trials No. 362 dated 08/14/2025). A subset of animals was infected with influenza A/California/07/2009 (H1N1) virus.
RESULTS: Administration of the drug to dyslipidemia mice resulted in a significant reduction in total cholesterol, triglycerides, and LDL levels, along with a significant increase in HDL. However, in the presence of influenza infection, the hypolipidemic effect of Prenophytol was markedly attenuated: only cholesterol levels decreased significantly, whereas changes in triglycerides, LDL, and HDL did not reach statistical significance.
CONCLUSIONS: Influenza infection diminishes the therapeutic efficacy of the Prenophytol in the treatment of dyslipidemia. These findings indicate that concomitant viral infections must be taken into account when designing dyslipidemia treatment regimens and conducting clinical trials of this drug.